MAIA Biotechnology, Inc. Altman Z-Score
MAIA|Modified Z-Score (book value) based on FY2024 data
MAIA Biotechnology, Inc.'s Altman Z-Score of -11.78 places the company in the "distress zone" used by the Altman model (below 1.23) for FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -11.78 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Distress Zone (< 1.23)
The score is below the 1.23 boundary used in the Altman model.
The Altman Z-Score uses 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2024 10-K filings.
5-Factor Decomposition
Working Capital / Total Assets
- Ratio
- 0.623
- Weight
- 0.717
- Contribution
- 0.446
Retained Earnings / Total Assets
- Ratio
- -8.590
- Weight
- 0.847
- Contribution
- -7.276
EBIT / Total Assets
- Ratio
- -1.670
- Weight
- 3.107
- Contribution
- -5.188
Book Equity / Total Liabilities
- Ratio
- 0.557
- Weight
- 0.420
- Contribution
- 0.234
Revenue / Total Assets
- Ratio
- 0.000
- Weight
- 0.998
- Contribution
- 0.000
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.623 | 0.717 | 0.446 |
| Retained Earnings / Total Assets | -8.590 | 0.847 | -7.276 |
| EBIT / Total Assets | -1.670 | 3.107 | -5.188 |
| Book Equity / Total Liabilities | 0.557 | 0.420 | 0.234 |
| Revenue / Total Assets | 0.000 | 0.998 | 0.000 |
| Total Z-Score | -11.78 | ||
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 24, 2026
Z-Score Zones
Safe Zone - score above the 2.9 boundary used in the Altman model.
Grey Zone - score between the 1.23 and 2.9 boundaries used in the Altman model.
Distress Zone - score below the 1.23 boundary used in the Altman model.